Emerging Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma

Presented by the Johns Hopkins School of Medicine

Supported by an educational grant from Celgene Corporation.

OVERVIEW
Multiple myeloma is a largely progressive and incurable disease where frequent second and later remissions are brief due to increasingly aggressive tumor behavior at each relapse. Fortunately, the treatment landscape for patients with relapsed refractory multiple myeloma (RRMM) has changed dramatically over the last several years, with promising new agents and triplet regimens. Frequent updates to National Comprehensive Cancer Network (NCCN) treatment guidelines, and the latest efficacy and safety data, combined with consideration of tumor features, patient characteristics, treatment history, duration and depth of response to prior treatment, as well as specific patient needs, have to be integrated in the decisional balance in order to offer RRMM patients the most ideal treatment and outcomes currently possible. This written, interactive, case-based activity will: review the most current US Food and Drug Administration therapy approvals along with updates to the NCCN treatment guidelines; evaluate the safety and efficacy of new and emerging therapeutic options, including immune-based therapies; and increase participants’ ability to implement the most appropriate treatment plans for their patients with RRMM.

GOAL
The goal of this activity is to provide hematology/oncology physicians, nurse practitioners, physician assistants, and nurses, as well as other healthcare providers who care for patients with RRMM with the most up-to-date information to optimize care and clinical outcomes.

TARGET AUDIENCE
This activity is intended for hematology/oncology physicians, nurse practitioners/physician assistants, and nurses, as well as other healthcare providers who are involved in the care of patients with relapsed and/or refractory multiple myeloma. No prerequisites required.

LEARNING OBJECTIVES
After participating in this activity, the participant will demonstrate the ability to:
  • •  EVALUATE the different types of FDA-approved agents for RRMM and the current NCCN guidelines for treating patients with RRMM.
  • •  REVIEW the safety and efficacy of investigational targeted- and immuno-therapies for RRMM patients.
  • •  DEVELOP patient-specific treatment based on tumor features, patient characteristics, treatment history/response, frailty score and cytogenetic considerations.

The Johns Hopkins School of Medicine and takes responsibility for the content, quality, and scientific integrity of this CME activity.

CE INFORMATION
Accreditation Statements
accme_logoThe Johns Hopkins School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians

Credit Designation Statements — The Johns Hopkins School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The estimated time to complete this activity: 60 minutes.

Release date: August 7, 2019     Expiration date: August 7, 2020

Policy On Presenter and Provider Disclosure
It is the policy of the Johns Hopkins School of Medicine that the speaker and provider globally disclose conflicts of interest. The Johns Hopkins School of Medicine OCME has established policies that will identify and resolve conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to presentation of the education.

Full Disclosure Policy Affecting CME Activities
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), Johns Hopkins School of Medicine Office of Continuing Medical Education (OCME) requires attested and signed global disclosure of the existence of all financial interests or relationships with commercial interest from any individual in a position to control the content of a CME activity sponsored by OCME. The following relationships have been reported for this activity:

Planner Disclosures
Dr. Ettinger reports receiving consulting fees from BeyondSpring Pharmaceuticals, Inc, Boehringer Ingelheim Vetmedica, Inc, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Genentech, Inc, and Guardant Health, Inc, and Sanofi-Aventis.

Participating Faculty Disclosures
Dr Voorhees reports receiving consulting fees/honoraria from TeneoBio for serving on an advisory board for protocol development; receiving consulting fees and honoraria from Oncopeptides AB for serving on an advisory board as an independent data review chair; receiving honoraria for serving on an advisory board for Adaptive Biotechnologies, Bristol-Myers Squibb Company, Celgene Corporation, Janssen, and Takeda Pharmaceuticals, Inc; and receiving consulting fees for serving as an independent data review chair for Novartis AG.

No other individual with the opportunity to affect this educational content has indicated any financial interests or relationships with a commercial entity.

Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

FACULTY
Johns Hopkins School of Medicine Chair and Planner
David S. Ettinger, MD

Alex Grass Professor in Oncology
Sidney Kimmel Comprehensive Cancer
Baltimore, Maryland

Faculty Author
Peter M. Voorhees, MD
Director, Outreach for Hematologic Malignancies
Plasma Cells Disorder Program
Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina

Peer Reviewer
Susan L. Gearhart, MD

Associate Professor of Surgery
Director of Pharmacy
Johns Hopkins School of Medicine
Baltimore, Maryland

OFF-LABEL PRODUCT DISCUSSION – No faculty member has indicated that their presentation will include information on off-label products.

DISCLAIMER – The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of Johns Hopkins School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

CONFIDENTIALITY DISCLAIMER FOR CME ACTIVITY PARTICIPANT
I certify that I am participating in this Johns Hopkins School of Medicine activity for CME-accredited training and/or educational purposes.

I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the “Privacy Regulations”). Protected health information is information about a person's health or treatment that identifies the person.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential. I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (eg, Facebook, Twitter, etc.), in any electronic messaging program or through any portable electronic device.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

"The Office of Continuing Medical Education at the Johns Hopkins School of Medicine, as provider of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only."

For CME questions, please contact the CME Office at 410-955-2959 or e-mail cmenet@jhmi.edu.
Johns Hopkins School of Medicine
Office of Continuing Medical Education
720 Rutland Avenue/ Turner 20
Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03) (Updated 4/09 and 3/14)

HARDWARE & SOFTWARE REQUIREMENTS
Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.

ACTIVITY INSTRUCTIONS
The following is an interactive case module designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited preassessment, an interactive case study, and a CE postassessment and evaluation. All 3 sections must be completed to receive CE credit. A certificate of participation will be available online immediately following successful completion of the activity.

Preassessment

Emerging Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma
Peter M. Voorhees, MD

Postassessment and Evaluation

This activity was developed in collaboration with ASiM.


© 2019 - Hematology Consults